|
Jun 25
|
Argenx (ARGX) Surges 11.7%: Is This an Indication of Further Gains?
|
|
Jun 24
|
Travere (TVTX) Stock Jumps 5.2%: Will It Continue to Soar?
|
|
Jun 14
|
BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024
|
|
Jun 13
|
BeiGene and NewBridge Pharmaceuticals FZ LLC Mutually Agree to Conclude BRUKINSA® (Zanubrutinib) Partnership in the Middle East and Africa (MENA) Region
|
|
Jun 13
|
BeiGene, Ltd. (NASDAQ:BGNE) Shares Could Be 47% Below Their Intrinsic Value Estimate
|
|
May 14
|
BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024
|
|
May 11
|
The BeiGene, Ltd. (NASDAQ:BGNE) First-Quarter Results Are Out And Analysts Have Published New Forecasts
|
|
May 9
|
BeiGene First Quarter 2024 Earnings: Beats Expectations
|
|
May 9
|
Decoding BeiGene Ltd (BGNE): A Strategic SWOT Insight
|
|
May 9
|
India’s Sensex Down 0.4%, Dragged by Industrial, Tech Stocks
|
|
May 8
|
BeiGene Reports First Quarter 2024 Financial Results and Business Updates
|
|
Apr 26
|
BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report
|
|
Apr 25
|
20 Countries with the Highest Rates of Stomach Cancer in the World
|
|
Apr 24
|
Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting
|
|
Apr 23
|
With 42% ownership of the shares, BeiGene, Ltd. (NASDAQ:BGNE) is heavily dominated by institutional owners
|
|
Apr 23
|
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
|
|
Mar 27
|
Shareholders in BeiGene (NASDAQ:BGNE) have lost 54%, as stock drops 8.5% this past week
|
|
Mar 17
|
30 Biggest Biotechnology Companies in the World
|
|
Mar 14
|
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
|
|
Mar 14
|
UPDATE 1-US FDA approves BeiGene's esophageal cancer therapy
|